# Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults

> **NCT00741637** · PHASE2 · COMPLETED · sponsor: **International Vaccine Institute** · enrollment: 32 (actual)

## Conditions studied

- Cholera
- Vibrio Infections
- Diarrhea

## Interventions

- **BIOLOGICAL:** CholeraGarde®
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00741637
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-04
- **Final completion:** 2011-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741637, "Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00741637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*